To broadly investigate the role of PRL-3 in cancer aggressiveness, we generated doxycycline-inducible cell lines in three cancer types: Jurkat (T-cell acute lymphoblastic leukemia), RD (embryonal rhabdomyosarcoma), and HCT116 (colon carcinoma). This evidence concerns the gene PTP4A3 and T-cell acute lymphoblastic leukemia.